Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

CoDa Therapeutics

Request full access

Therapeutics for tissue repair targeting gap junction modulation

San Diego, United StatesFounded 2005Biotech & Life Sciences

About CoDa Therapeutics

Originally founded as CoDa Therapeutics in 2005, the company rebranded to Ocunexus Therapeutics and operates as a clinical-stage biopharmaceutical firm. The company was established based on inventions from the laboratories of Professor Colin Green of the University of Auckland and Professor David Becker of University College London. Colin Green continues to serve as the Founder & Chief Scientific Officer. Ocunexus focuses on developing treatments for tissue repair and wound care by targeting the modulation of gap junctions, specifically the protein connexin43 (Cx43).

The company's lead product candidate is Nexagon®, a natural, unmodified antisense oligonucleotide designed to downregulate the expression of Cx43. This protein is often overexpressed in pathological conditions and injuries, leading to inflammation and hindering the healing process. By modulating Cx43, Nexagon® aims to reduce lesion spread, swelling, inflammation, and scarring, while improving wound closure rates across various tissue types, including the eye, skin, and nerves. The technology represents a novel approach by targeting the body's natural healing mechanisms.

Ocunexus' business model involves developing its proprietary compounds through clinical trials and entering into licensing agreements for commercialization. In a significant milestone, Ocunexus entered into a worldwide licensing agreement with Eyevance Pharmaceuticals (later acquired by Santen) for Nexagon® for the orphan indication of persistent corneal epithelial defect (PED). This collaboration progressed Nexagon® into later-stage clinical trials. The company's pipeline has also included Peptagon™, a peptide-based medicine for blocking gap junctions. Ocunexus targets unmet clinical needs in ophthalmology and other indications characterized by pathological connexin43 hemichannel overexpression.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
54.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Dec 2021 $0 — Inflammx Therapeutics —
DEBTDebt Jun 2016 $750K — Undisclosed —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

CoDa Therapeutics website traffic

Latest recorded traffic for CoDa Therapeutics is 0 monthly website visits. CoDa Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

CoDa Therapeutics in the San Diego ecosystem

Live from Dealroom

The CoDa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • GBS Venture Partners

Series B and later1 investor entered at this stage

  • Square 1 Bank

Other known investors3 additional known investors

  • Inflammx Therapeutics
  • The University of Auckland
  • University College London
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · San Diego HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about CoDa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See CoDa Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.